EXHIBIT 107

 

Calculation of Filing Fee Table

F-1

(Form Type)

TC BioPharm (Holdings) plc

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 
   Security Type  Security Class Title  Fee Calculation or Carry Forward Rule   Amount Registered   Proposed Maximum Offering Price Per Share(1)   Maximum Aggregate Offering Price(1)(2)   Fee Rate   Amount of Registration Fee   Carry Forward Form Type   Carry Forward File Number   Carry Forward Initial effective date   Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward 
Newly Registered Securities
Fees Previously Paid   Equity  Ordinary shares, £0.01 par value per share(2) 457(o)     4,999,999 (3)  $1.15   $ 5,749,999     .0000927   $ 533.03                                                
                                                         
Carry Forward Securities
Carry Forward Securities                                                        
  Total Offering Amounts   $ 5,749,999         $ 533.03                      
   Total Fees Previously Paid               852.84                     
  Total Fee Offsets              -                     
   Net Fee Due             $ -                     

 

(1) Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended, or the Securities Act. Includes the offering price of ordinary shares represented by American Depositary Shares, or ADSs, that the Underwriters have the option to purchase to cover over-allotments, if any.
   
 (2) These ordinary shares are represented by ADSs, each of which represents one ordinary share of the registrant. ADSs issuable upon deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form F-6 (File No. 333-262149). In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (“Securities Act”), the securities being registered hereunder include such indeterminate number of ordinary shares as may be issuable with respect to the ordinary shares being registered hereunder as a result of stock splits, stock dividends or similar anti-dilutive transactions.
   
(3) Includes 652,173 additional ADSs that the underwriters have the option to purchase to cover over-allotments, if any.